Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. (HBIO) is dated October 2, 2025. The filing addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with Nasdaq listing standards rather than financial performance metrics.
Material Changes
- Listing Transfer: The Company's common stock has been transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 3, 2025.
- Compliance Extension: Nasdaq granted the Company an additional 180-day "Second Compliance Period" until March 30, 2026, to regain compliance with the minimum bid price requirement.
- Deficiency: The stock price had closed below $1.00 per share for 30 consecutive business days, triggering the initial deficiency notice in April 2025.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and will consider available options to regain compliance, including effecting a reverse stock split if necessary. The Company must maintain a closing bid price of $1.00 or more for 10 consecutive business days before March 30, 2026, to receive written confirmation of compliance.
Risks: There is no assurance the Company will regain compliance. Failure to meet the requirement by the end of the Second Compliance Period will result in delisting. The Company retains the right to appeal a delisting determination to a hearings panel.
Investor Verification Checklist
- Verify the current trading venue is the Nasdaq Capital Market (effective Oct 3, 2025).
- Monitor the daily closing bid price to ensure it meets the $1.00 threshold for 10 consecutive days.
- Watch for future announcements regarding a potential reverse stock split.
- Note the final deadline for compliance is March 30, 2026.